Tempus

Tempus: Personalized Healthcare Solutions Powered by Artificial Intelligence

Tempus is a leading digital health company that harnesses the power of artificial intelligence to deliver personalized healthcare solutions. With their extensive library of clinical and molecular data, they are revolutionizing the way healthcare providers approach patient care, starting with cancer.

Key Features:

• AI Clinical Assistant: Tempus One, an AI-enabled clinical assistant, provides clinicians with direct access to patient insights using generative AI technology.
• Genomic Profiling: Tempus offers genomic profiling and algorithmic tests, empowering physicians to make more informed treatment decisions.
• Clinical Trial Matching: The platform enables fast and up-to-date search for clinical trials based on specific criteria.
• Digital Pathology: Tempus provides digital pathology services, including Tempus Pixel for therapy response evaluation and specialized disease areas such as lung, breast, neuro, and cardio.
• Sequencing and Data Collaborations: Tempus offers sequencing services and fosters data collaborations for enhanced drug development.
• Clinical Research Services: Tempus provides services for clinical trial enrollment and offers Tempus PRO™, a platform tailored to neurology and psychiatry.
• EHR Integration: Tempus supports seamless data access and management through EHR integration.
• Publications: Tempus regularly publishes research, webinars, and other resources to keep the healthcare community informed about the latest advancements in personalized healthcare.

Use Cases:

• Providers: Tempus helps physicians make more informed treatment decisions by providing access to patient insights and genomic profiling.
• Life Sciences: Tempus assists pharmaceutical and biotech companies in improving drug development through data collaborations and genomic profiling.
• Patients: Tempus empowers patients by helping them find unique and optimal therapy options based on their individual health profiles.

Notable Achievements:

• Tempus’ xT Platform expands personalized therapeutic opportunities for cancer patients.
• The FDA has granted Tempus Breakthrough Device Designation for its HLA-LOH assay, recognizing it as a companion diagnostic (CDx) test.
• Tempus launched Tempus xR, a standalone RNA next-generation sequencing assay.
• Tempus has established partnerships with 90% of the top 20 pharma oncology companies and over 200 biopharma partnerships.
• Over 50% of all Academic Medical Centers and oncologists in the US are connected to Tempus.
• Tempus has a vast collection of over 6,000,000 de-identified research records and has identified more than 24,000 patients for potential enrollment into clinical trials within their network.